ZURA BIO LIMITED Proceeds from Common Stock Issued
ZURA BIO LIMITED (ZURA) reported Proceeds from Common Stock Issued of $56.68 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-19
- ZURA BIO LIMITED proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00.
- ZURA BIO LIMITED proceeds from issuance of common stock for the quarter ending 2023-09-30 was $0.00.
- ZURA BIO LIMITED proceeds from issuance of common stock for the quarter ending 2023-06-30 was $0.00.
- ZURA BIO LIMITED proceeds from issuance of common stock for the quarter ending 2023-03-31 was $56.68M.
- ZURA BIO LIMITED proceeds from issuance of common stock for fiscal 2023 was $56.68M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 7 month | Proceeds from Issuance of Common Stock 7 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 10 month | Proceeds from Issuance of Common Stock 10 month as first filed | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $56.68M 10-K · filed 2025-03-25 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $56.68M 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $56.68M 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | $56.68M 10-Q · filed 2024-05-09 | ||||||||
| 2023-03-16 | $56.70M 10-K · filed 2026-03-19 | ||||||||
| 2021-12-31 | $138.00M 10-K · filed 2023-03-28 | $25.00K 10-K · filed 2022-04-11 | |||||||
| 2021-09-30 | $138.00M 10-Q · filed 2022-11-14 | $25.00K 10-Q · filed 2021-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |